A practical reference on cyclic heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-04-11 and is reviewed periodically as new material appears.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-MSH |
| Molecular mass | Approximately 1025 Da | Peptide-scale molecule |
| Route | Subcutaneous injection | Intranasal form used in early research |
| Common synonyms | PT-141; bremelanotide acetate | Research code and salt form |
| Typical storage | 2-8 °C, protected from light | Unopened vial condition |
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Techniques have been developed to produce nanotubes in sizeable quantities, including arc discharge, laser ablation, chemical vapor deposition (CVD) and high-pressure carbon monoxide disproportionation (HiPCO). Among these arc discharge, laser ablation are batch by batch process, Chemical Vapor Deposition can be used both for batch by batch or continuous processes, and HiPCO is gas phase continuous process. Most of these processes take place in a vacuum or with process gases. The CVD growth method is popular, as it yields high quantity and has a degree of control over diameter, length and morphology. Using particulate catalysts, large quantities of nanotubes can be synthesized by these methods, and industrialisation is well on its way, with several CNT and CNT fibers factory around the world. One problem of CVD processes is the high variability in the nanotube's characteristics. The HiPCO process advances in catalysis and continuous growth are making CNTs more commercially viable. The HiPCO process helps in producing high purity single-walled carbon nanotubes in higher quantity. The HiPCO reactor operates at high temperature 900–1100 °C and high pressure ~30–50 bar. It uses carbon monoxide as the carbon source and iron pentacarbonyl or nickel tetracarbonyl as a catalyst. These catalysts provide a nucleation site for the nanotubes to grow, while cheaper iron-based catalysts like Ferrocene can be used for CVD process. Vertically aligned carbon nanotube arrays are also grown by thermal chemical vapor deposition.
Two people were killed by Russian shelling in Ukrainsk, Donetsk Oblast. One person was killed in a separate attack in Komar. Russia launched an air attack on Myrhorod Air Base in Poltava Oblast. The Ukrainian Air Force acknowledged damage, with two of the base's six Su-27s destroyed by an Iskander missile with a cluster warhead. A drone attack was reported in Sevastopol and other parts of Crimea, with the Ukrainian Air Force later claiming to have struck an ammunition dump using six Storm Shadow cruise missiles. The ammunition dump was also believed to host a "Shahed drone warehouse". Russian sources claimed that five aerial targets were shot down. Ukrainian drone attacks left parts of Belgorod Oblast without power. Ukrainian media reported that a drone strike the Oskol Electrometallurgical Plant, Russia's only full-cycle metallurgical enterprise, in Stary Oskol. Scouts from the Ukrainian Rubizh Brigade captured "several dozen Russian soldiers", mostly mobilised conscripts, in an unspecified location. Dutch defence minister Kajsa Ollongren announced that the export permits allowing the export of 24 F-16s to Ukraine had been granted, with their arrival set on a "confidential" date. The SBU claimed to have foiled a coup by a Russian-backed group against the Ukrainian government that was scheduled on 30 July. Russia claimed to have captured an ATACMS missile guidance system intact and was studying it to "identify any weak spots".
Isobaric tags for relative and absolute quantitation (iTRAQ) is an isobaric labeling method used in quantitative proteomics by tandem mass spectrometry to determine the amount of proteins from different sources in a single experiment. It uses stable isotope labeled molecules that can be covalent bonded to the N-terminus and side chain amines of proteins.
Sources: en.wikipedia.org
== Veterinary medicine == HbA1c testing has not been found useful in the monitoring during the treatment of cats and dogs with diabetes, and is not generally used; monitoring of fructosamine levels is favoured instead.
== History == The proposal that proteins were linear chains of α-amino acids was made nearly simultaneously by two scientists at the same conference in 1902, the 74th meeting of the Society of German Scientists and Physicians, held in Karlsbad. Franz Hofmeister made the proposal in the morning, based on his observations of the biuret reaction in proteins. Hofmeister was followed a few hours later by Emil Fischer, who had amassed a wealth of chemical details supporting the peptide-bond model. For completeness, the proposal that proteins contained amide linkages was made as early as 1882 by the French chemist E. Grimaux. Despite these data and later evidence that proteolytically digested proteins yielded only oligopeptides, the idea that proteins were linear, unbranched polymers of amino acids was not accepted immediately. Some scientists such as William Astbury doubted that covalent bonds were strong enough to hold such long molecules together; they feared that thermal agitations would shake such long molecules asunder. Hermann Staudinger faced similar prejudices in the 1920s when he argued that rubber was composed of macromolecules. Thus, several alternative hypotheses arose. The colloidal protein hypothesis stated that proteins were colloidal assemblies of smaller molecules. This hypothesis was disproved in the 1920s by ultracentrifugation measurements by Theodor Svedberg that showed that proteins had a well-defined, reproducible molecular weight and by electrophoretic measurements by Arne Tiselius that indicated that proteins were single molecules.
=== Other interactions === SSRIs, including citalopram, can increase the risk of bleeding, especially when coupled with aspirin, NSAIDs, warfarin, or other anticoagulants. Taking citalopram with omeprazole may cause higher blood levels of citalopram. This is a potentially dangerous interaction, so dosage adjustments may be needed or alternatives may be prescribed.
Sources: en.wikipedia.org
=== Medieval period === In the Golden age of the Islamic Caliphate (medieval time in Europe), a form of passport was the bara'a, a receipt for taxes paid. Border controls were in place to ensure that only people who paid their zakah (for Muslims) or jizya (for dhimmis) taxes could travel freely between different regions of the Caliphate; thus, the bara'a receipt was a "basic passport". In medieval Europe, passports were issued as early as the reign of Henry V of England to help his subjects prove who they were in foreign lands. The earliest reference to these documents is found in an act of Parliament, the Safe Conducts Act 1414 (2 Hen. 5. Stat. 1. c. 6). In 1540, granting travel documents in England became a role of the Privy Council of England, and it was around this time that the term "passport" was used. In 1794, issuing British passports became the job of the Office of the Secretary of State. The 1548 Imperial Diet of Augsburg required the public to hold imperial documents for travel, at the risk of permanent exile. During World War I, European governments introduced border passport requirements for security reasons, and to control the emigration of people with useful skills. These controls remained in place after the war, becoming a standard, though controversial, procedure. British tourists of the 1920s complained, especially about attached photographs and physical descriptions, which they considered led to a "nasty dehumanization". Beginning in the mid-19th century, the Ottoman Empire established quarantine stations on many of its borders to control disease.
=== Limitations === The UK Government's Department of Health compiled a factsheet in 2014, in which it is stated that the key limitations to well-being, quality of life and life satisfaction research are that:
Brower has been credited with popularizing the term "ecological chemistry" which appeared in the title of a paper he published in Science in 1968 and again the following year in an article he wrote for Scientific American, where the term also appeared on the front cover under an image of a giant bluejay towering over two monarch butterflies. The specialized Journal of Chemical Ecology was established in 1975, and the Journal Chemoecology was founded in 1990. In 1984, the International Society of Chemical Ecology was established and in 1996, the Max Planck Institute of Chemical Ecology was founded in Jena, Germany.
== History == In 1998, MuscleTech launched Cell-Tech, a creatine-carbohydrate-alpha lipoic acid supplement. In September 2018, Muscletech is partnering up to Rob Gronkowski to create a high-protein candy bar. In October 2018, MuscleTech partnered with Homes For Our Troops. In April 2019, MuscleTech had partnered up with Tough Mudder. In July 2019, MuscleTech launched the Prime Series, a private label sports nutrition line exclusive to Amazon. In April 2021, MuscleTech is announced the addition of a new general manager. MuscleTech, through its parent company Iovate Health Sciences, is a partner of the Metabolism & Sports Science Lab at the University of Toronto. In February 2022, MuscleTech announced they are looking for their next Brand Superstar. In April 2024, Muscletech and Trust Group came to an agreement for Trust Group to manufacture and market MuscleTech products in the Brazilian market.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.
Earlier approaches were largely hormonal or psychological in focus, whereas this compound acts on central melanocortin signalling. It is not a vasodilator and does not share the mechanism of phosphodiesterase inhibitors. Head-to-head comparative data are limited.
Placebo responses in desire trials are large, so the average drug-placebo separation is small. Reporting therefore relies on validated questionnaires with statistical ranges. Individual responses vary widely.
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.